Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Protagonist Therapeutics, Inc. (PTGX) had Free Cash Flow per Share of $1.50 for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$5.55M |
|
$-34.77M |
|
-- |
|
$5.55M |
|
$47.59M |
|
$-42.04M |
|
$7.44M |
|
$-34.60M |
|
$-34.60M |
|
$-34.77M |
|
$-34.77M |
|
$-34.77M |
|
$-34.77M |
|
$-42.04M |
|
$-44.22M |
|
63.51M |
|
63.51M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$602.53M |
|
$4.11M |
|
$115.48M |
|
$718.01M |
|
$35.51M |
|
-- |
|
$14.48M |
|
$49.99M |
|
$668.02M |
|
$668.02M |
|
$668.02M |
|
62.11M |
|
| Cash Flow Statement Financials | |
$96.58M |
|
$-39.59M |
|
$14.37M |
|
$97.47M |
|
$168.83M |
|
$71.36M |
|
$24.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.97 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-758.04% |
|
-758.04% |
|
-- |
|
-623.86% |
|
-626.96% |
|
$95.22M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-5.21% |
|
-5.21% |
|
-4.84% |
|
-5.21% |
|
$10.76 |
|
|
Free Cash Flow per Share |
$1.50 |
$1.52 |
|